Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 14,256 | 14,503 | 17,565 | 15,693 | 13,749 |
| Gross Profit | 14,256 | 14,503 | 17,565 | 15,693 | 13,749 |
| Operating Expenses | 29,961 | 25,710 | 23,805 | 24,453 | 29,872 |
| Operating Income | -15,705 | -11,207 | -6,240 | -8,760 | -16,123 |
| Interest Expense | 644 | 629 | 623 | 609 | 568 |
| Other Income | 1,128 | 1,434 | 1,847 | 1,786 | 2,504 |
| Pre-tax Income | -15,221 | -10,402 | -5,016 | -7,583 | -14,187 |
| Income Tax | 1,308 | 1,262 | 3,494 | 1,367 | 1,458 |
| Net Income Continuous | -16,529 | -11,664 | -8,510 | -8,950 | -15,645 |
| Net Income | $-16,529 | $-11,664 | $-8,510 | $-8,950 | $-15,645 |
| EPS Basic Total Ops | -0.34 | -0.24 | -0.20 | -0.17 | -0.28 |
| EPS Basic Continuous Ops | -0.34 | -0.24 | -0.20 | -0.17 | -0.28 |
| EPS Diluted Total Ops | -0.34 | -0.24 | -0.20 | -0.17 | -0.28 |
| EPS Diluted Continuous Ops | -0.34 | -0.24 | -0.20 | -0.17 | -0.28 |
| EPS Diluted Before Non-Recurring Items | -0.34 | -0.24 | -0.17 | N/A | N/A |
| EBITDA(a) | $-15,857 | $-11,129 | $-6,251 | $-8,730 | $-15,985 |